Quantcast

Latest Dextromethorphan Stories

2014-10-08 08:27:11

ALISO VIEJO, Calif., Oct. 8, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from the phase II trial evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease (AD) and the results of the phase IV PRISM II study evaluating NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) for the treatment of pseudobulbar affect (PBA) in patients with AD will be presented at the American Neurological Association's (ANA)...

2014-09-16 08:30:38

First-Ever Children's Cough and Cold Patented Medicines to Combine Trusted, Effective Ingredients with Real Cocoa for a Chocolate Flavor to Help Improve Dosing Compliance WESTPORT, Conn., Sept. 16, 2014 /PRNewswire/ -- In a new national survey(1) of U.S. parents of school-age children (ages 4-13), almost 40% report that it isn't always easy to give their children over-the-counter liquid cough/cold medicines. One third (34%) of parents believe the taste of the medicine impacts how easy it is...

2014-08-26 08:31:43

--Study to Utilize Sequential Parallel Comparison Design to Minimize Placebo Response, Same Design Utilized in AVP-923 Phase II Study in Agitation in Alzheimer's Disease-- ALISO VIEJO, Calif., Aug. 26, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the enrollment of the first patient into a phase II study to evaluate the efficacy, safety and tolerability of AVP-786 for the adjunctive treatment of major depressive disorder (MDD). AVP-786 is a novel...

2014-08-05 16:27:40

ALISO VIEJO, Calif., Aug. 5, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and nine months ended June 30, 2014. Quarterly Financial Highlights -- Total company net revenues of $28.6 million. -- Net NUEDEXTA® sales of $26.5 million. -- Cash, cash equivalents, and restricted investments of $87.6 million as of June 30, 2014. "We had a great quarter across all aspects of our business. I am delighted with...

2014-07-16 08:29:14

--Interim Results Show NUEDEXTA Provides Meaningful Reduction of PBA Episodes and is Generally Well Tolerated in Alzheimer's Disease/Dementia Population-- ALISO VIEJO, Calif., July 16, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced interim data from the phase IV PRISM II study showing that treatment with NUEDEXTA(®) substantially reduced symptoms of pseudobulbar affect (PBA) in patients with Alzheimer's disease/dementia. PBA is a distressing neurologic...

2014-06-30 20:22:37

ALISO VIEJO, Calif., June 30, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to pseudobulbar affect (PBA), a neurological condition characterized by disruptive, uncontrollable episodes of laughing or crying, and NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate), the only FDA-approved product for the treatment of PBA, will be presented at the Alzheimer's Association International Conference (AAIC), being held at the Bela...

2014-05-30 08:25:39

ALISO VIEJO, Calif., May 30, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data related to the prevalence and treatment of pseudobulbar affect (PBA), a distressing neurological condition characterized by uncontrollable laughing or crying, will be presented at the following conferences in June. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO Joint Congress of European Neurology (EFNS-ENS), May 31 - June 3, 2014, Istanbul -- Burden of...

2014-05-27 08:29:52

ALISO VIEJO, Calif., May 27, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced completion of patient enrollment in the company's phase II, placebo controlled study testing AVP-923 for the treatment of agitation in Alzheimer's disease patients. Top-line results from this study are expected late September/early October. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO "Final completion of enrollment in this study is an important milestone for...

2014-05-06 16:32:33

ALISO VIEJO, Calif., May 6, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and six months ended March 31, 2014. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO Quarterly Financial Highlights -- Total company net revenues of $26.9 million -- Net NUEDEXTA® sales of $24.4 million -- Cash, cash equivalents, and restricted investments of $56.5 million as of March 31, 2014. "We are extremely pleased...

2014-04-30 16:30:05

ALISO VIEJO, Calif., April 30, 2014, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. District Court for the District of Delaware has ruled in favor of Avanir in the company's patent infringement lawsuit against Par Pharmaceuticals, Inc. and Impax Laboratories, Inc. in conjunction with their Abbreviated New Drug Applications ('ANDAs') for generic versions of NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules for the...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related